1
|
Heredia-Guerrero SC, Evers M, Keppler S, Schwarzfischer M, Fuhr V, Rauert-Wunderlich H, Krügl A, Nedeva T, Grieb T, Pickert J, Koch H, Steinbrunn T, Bayrhof OJ, Bargou RC, Rosenwald A, Stühmer T, Leich E. Functional Investigation of IGF1R Mutations in Multiple Myeloma. Cancers (Basel) 2024; 16:2139. [PMID: 38893258 PMCID: PMC11171363 DOI: 10.3390/cancers16112139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2024] [Revised: 05/22/2024] [Accepted: 05/22/2024] [Indexed: 06/21/2024] Open
Abstract
High expression of the receptor tyrosine kinase (RTK) insulin-like growth factor-1 receptor (IGF1R) and RTK mutations are associated with high-risk/worse prognosis in multiple myeloma (MM). Combining the pIGF1R/pINSR inhibitor linsitinib with the proteasome inhibitor (PI) bortezomib seemed promising in a clinical trial, but IGF1R expression was not associated with therapy response. Because the oncogenic impact of IGF1R mutations is so far unknown, we investigated the functional impact of IGF1R mutations on survival signaling, viability/proliferation and survival response to therapy. We transfected four human myeloma cell lines (HMCLs) with IGF1RWT, IGF1RD1146N and IGF1RN1129S (Sleeping Beauty), generated CRISPR-Cas9 IGF1R knockouts in the HMCLs U-266 (IGF1RWT) and L-363 (IGF1RD1146N) and tested the anti-MM activity of linsitinib alone and in combination with the second-generation PI carfilzomib in seven HMCLs. IGF1R knockout entailed reduced proliferation. Upon IGF1R overexpression, survival signaling was moderately increased in all HCMLs and slightly affected by IGF1RN1129S in one HMCL, whereby the viability remained unaffected. Expression of IGF1RD1146N reduced pIGF1R-Y1135, especially under serum reduction, but did not impact downstream signaling. Linsitinib and carfilzomib showed enhanced anti-myeloma activity in six out of seven HMCL irrespective of the IGF1R mutation status. In conclusion, IGF1R mutations can impact IGF1R activation and/or downstream signaling, and a combination of linsitinib with carfilzomib might be a suitable therapeutic approach for MM patients potentially responsive to IGF1R blockade.
Collapse
Affiliation(s)
| | - Marietheres Evers
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Sarah Keppler
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Marlene Schwarzfischer
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Viktoria Fuhr
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Hilka Rauert-Wunderlich
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Anne Krügl
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Theodora Nedeva
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Tina Grieb
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Julia Pickert
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Hanna Koch
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Torsten Steinbrunn
- Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany;
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
| | - Otto-Jonas Bayrhof
- Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany (R.C.B.); (T.S.)
| | - Ralf Christian Bargou
- Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany (R.C.B.); (T.S.)
| | - Andreas Rosenwald
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| | - Thorsten Stühmer
- Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany (R.C.B.); (T.S.)
| | - Ellen Leich
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany (M.E.); (H.R.-W.); (A.K.); (T.N.); (T.G.); (A.R.)
| |
Collapse
|
2
|
Liu H, Wang G, Huang Y, Zhao C, Chen J, Wang X. Identification specific miRNA in t(4;14) multiple myeloma based on miRNA-mRNA expressing profile correlation analysis. J Cell Biochem 2019; 120:2454-2468. [PMID: 30230597 DOI: 10.1002/jcb.27537] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2018] [Accepted: 08/06/2018] [Indexed: 01/24/2023]
Abstract
BACKGROUND Multiple myeloma (MM) is a common malignancy belonging to the hematological system. The translocation t(4;14)(p16.3;q32.3) is a critical cytogenetic change of MM, which is presenting a poor prognosis. The specific microRNAs (miRNAs) that are involved in t(4;14) myeloma are still unknown. Thus, the main purpose of this research was to identify specific miRNAs in t(4;14) positive myeloma. METHODS The expression profiles of miRNA and messenger RNA (mRNA) in t(4; 14) positive and negative samples were obtained from the gene expression omnibus data series. The miRNA-mRNA regulatory network was constructed based on two self-defined regulation models. Subsequently, we performed the topology analysis for mining the hub genes, and Pearson's correlation coefficient analysis was used to calculate the relevance of the hub genes and specific miRNAs. RESULTS Thirteen differentially expressed miRNAs and 206 differential mRNAs were extracted between t(4;14) positive group and negative group. The network consisted of 8 miRNAs and 154 mRNAs in 2 reverse regulated models, which showed a total of 485 interactions, including 376 cis-regulated and 109 trans-regulated relationships. The miR-125a-3p, miR-125a-5p, miR-99b-5p, and let-7e were powerful miRNAs correlating with the FGFR3, MAP1B, MYRIP, and CDC42BPA under the relevance analysis in the subnetwork. CONCLUSION In our study, a distinctive correlation analysis of miRNA-mRNA was established to excavate specific miRNAs and hub target mRNAs in patients with t(4;14), but it was only a matter of theoretical principles. The further experimental explorations are needed to confirm valuable diagnostic and therapeutic symbols specific associated with t(4;14) in the future.
Collapse
Affiliation(s)
- Huimin Liu
- Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.,Medical School of Medicine, Nantong University, Nantong, Jiangsu, China
| | - Guihua Wang
- Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.,Medical School of Medicine, Nantong University, Nantong, Jiangsu, China
| | - Ying Huang
- Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.,Medical School of Medicine, Nantong University, Nantong, Jiangsu, China
| | - Chunmei Zhao
- Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.,Medical School of Medicine, Nantong University, Nantong, Jiangsu, China
| | - Jing Chen
- Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.,Medical School of Medicine, Nantong University, Nantong, Jiangsu, China
| | - Xudong Wang
- Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.,Medical School of Medicine, Nantong University, Nantong, Jiangsu, China.,Clinical Biobank, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
| |
Collapse
|
3
|
Xie HY, Xing CY, Wei BJ, Xu X, Wu J, Chen LM, Cao GQ, Chen H, Chen KJ, Yin SY, Wu LM, Zhou L, Zheng SS. Association of IGF1R polymorphisms with the development of HBV-related hepatocellular carcinoma. ACTA ACUST UNITED AC 2014; 84:264-70. [PMID: 24758241 DOI: 10.1111/tan.12360] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Revised: 03/04/2014] [Accepted: 03/25/2014] [Indexed: 02/05/2023]
Affiliation(s)
- H.-Y. Xie
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - C.-Y. Xing
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - B.-J. Wei
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - X. Xu
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - J. Wu
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - L.-M. Chen
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - G.-Q. Cao
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - H. Chen
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - K.-J. Chen
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - S.-Y. Yin
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - L.-M. Wu
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - L. Zhou
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| | - S.-S. Zheng
- Division of Hepatobiliary Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health. Key Laboratory of Organ Transplantation, Collaborative innovation center for Diagnosis treatment of infectious diseases; Zhejiang University School of Medicine; Hangzhou China
| |
Collapse
|
4
|
Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, Seke Etet PF. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 2013. [PMID: 23207292 DOI: 10.1530/erc-12-0324] [Citation(s) in RCA: 189] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Insulin, IGF1, and IGF2 are the most studied insulin-like peptides (ILPs). These are evolutionary conserved factors well known as key regulators of energy metabolism and growth, with crucial roles in insulin resistance-related metabolic disorders such as obesity, diseases like type 2 diabetes mellitus, as well as associated immune deregulations. A growing body of evidence suggests that insulin and IGF1 receptors mediate their effects on regulating cell proliferation, differentiation, apoptosis, glucose transport, and energy metabolism by signaling downstream through insulin receptor substrate molecules and thus play a pivotal role in cell fate determination. Despite the emerging evidence from epidemiological studies on the possible relationship between insulin resistance and cancer, our understanding on the cellular and molecular mechanisms that might account for this relationship remains incompletely understood. The involvement of IGFs in carcinogenesis is attributed to their role in linking high energy intake, increased cell proliferation, and suppression of apoptosis to cancer risks, which has been proposed as the key mechanism bridging insulin resistance and cancer. The present review summarizes and discusses evidence highlighting recent advances in our understanding on the role of ILPs as the link between insulin resistance and cancer and between immune deregulation and cancer in obesity, as well as those areas where there remains a paucity of data. It is anticipated that issues discussed in this paper will also recover new therapeutic targets that can assist in diagnostic screening and novel approaches to controlling tumor development.
Collapse
Affiliation(s)
- Sefirin Djiogue
- Department of Animal Biology and Physiology, University of Yaoundé 1, PO Box 812, Yaoundé, Cameroon
| | | | | | | | | | | | | |
Collapse
|
5
|
Dimberg LY, Dimberg A, Ivarsson K, Fryknäs M, Rickardson L, Tobin G, Ekman S, Larsson R, Gullberg U, Nilsson K, Öberg F, Wiklund HJ. Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma. BMC Cancer 2012; 12:318. [PMID: 22838736 PMCID: PMC3488543 DOI: 10.1186/1471-2407-12-318] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2012] [Accepted: 07/12/2012] [Indexed: 03/20/2023] Open
Abstract
Background Multiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an increased activation of Signal transducer and activator of transcription (Stat)1. The role of Stat1 in MM has not been elucidated, but Stat1 has in several studies been ascribed a pro-apoptotic role. Conversely, IL-6 induction of Stat3 is known to confer resistance to apoptosis in MM. Methods To delineate the role of Stat1 in IFN mediated sensitization to apoptosis, sub-lines of the U-266-1970 MM cell line with a stable expression of the active mutant Stat1C were utilized. The influence of Stat1C constitutive transcriptional activation on endogenous Stat3 expression and activation, and the expression of apoptosis-related genes were analyzed. To determine whether Stat1 alone would be an important determinant in sensitizing MM cells to apoptosis, the U-266-1970-Stat1C cell line and control cells were exposed to high throughput compound screening (HTS). Results To explore the role of Stat1 in IFN mediated apoptosis sensitization of MM, we established sublines of the MM cell line U-266-1970 constitutively expressing the active mutant Stat1C. We found that constitutive nuclear localization and transcriptional activity of Stat1 was associated with an attenuation of IL-6-induced Stat3 activation and up-regulation of mRNA for the pro-apoptotic Bcl-2 protein family genes Harakiri, the short form of Mcl-1 and Noxa. However, Stat1 activation alone was not sufficient to sensitize cells to Fas-induced apoptosis. In a screening of > 3000 compounds including bortezomib, dexamethasone, etoposide, suberoylanilide hydroxamic acid (SAHA), geldanamycin (17-AAG), doxorubicin and thalidomide, we found that the drug response and IC50 in cells constitutively expressing active Stat1 was mainly unaltered. Conclusion We conclude that Stat1 alters IL-6 induced Stat3 activity and the expression of pro-apoptotic genes. However, this shift alone is not sufficient to alter apoptosis sensitivity in MM cells, suggesting that Stat1 independent pathways are operative in IFN mediated apoptosis sensitization.
Collapse
Affiliation(s)
- Lina Y Dimberg
- Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, S- 751 85, Sweden
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|